Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
- PMID: 18483370
- DOI: 10.1158/1078-0432.CCR-07-4079
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
Abstract
Purpose: CT-011 is a humanized IgG1 monoclonal antibody that modulates the immune response through interaction with PD-1, a protein belonging to the B7 receptor family present on lymphocytes. The objectives of this phase I study were to assess the dose-limiting toxicities, to determine the maximum tolerated dose, and to study the pharmacokinetics of CT-011 administered once to patients with advanced hematologic malignancies.
Experimental design: Seventeen patients were treated with escalating doses of CT-011 ranging from 0.2 to 6 mg/kg. For pharmacokinetic analysis, blood samples were withdrawn from the patients before and immediately after treatment and at 24 hours, 48 hours, and on days 7, 14, and 21. CT-011 blood levels were assessed with a specific ELISA and derived concentrations were used to calculate pharmacokinetic parameters. Activation of the immune system was assessed by measuring peripheral blood CD4+, CD8+, and CD69+ lymphocytes.
Results: The study showed the antibody to be safe and well tolerated in this patient population. No single maximum tolerated dose was defined in this study. Clinical benefit was observed in 33% of the patients with one complete remission. Pharmacokinetic analyses show that serum Cmax and the AUC of CT-011 increased proportionally with dose. The median t1/2 of CT-011 ranged from 217 to 410 hours. Sustained elevation in the percentage of peripheral blood CD4+ lymphocytes was observed up to 21 days following CT-011 treatment.
Conclusions: A single administration of 0.2 to 6.0 mg/kg of CT-011 is safe and well tolerated in patients with advanced hematologic malignancies.
Similar articles
-
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.Clin Cancer Res. 2010 Feb 15;16(4):1256-63. doi: 10.1158/1078-0432.CCR-09-1267. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145186 Clinical Trial.
-
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.Clin Cancer Res. 2010 Jan 15;16(2):699-710. doi: 10.1158/1078-0432.CCR-09-1365. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068101 Clinical Trial.
-
Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.Cancer Chemother Pharmacol. 2011 Sep;68(3):733-41. doi: 10.1007/s00280-010-1544-1. Epub 2010 Dec 16. Cancer Chemother Pharmacol. 2011. PMID: 21161528 Clinical Trial.
-
Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma.Clin Pharmacol Ther. 2017 Aug;102(2):305-312. doi: 10.1002/cpt.587. Epub 2017 Jun 9. Clin Pharmacol Ther. 2017. PMID: 27981577 Review.
-
[Pharmacokinetics and impaired organic functions].Bull Cancer. 2011 Nov;98(11):1347-54. doi: 10.1684/bdc.2011.1465. Bull Cancer. 2011. PMID: 22024557 Review. French.
Cited by
-
Dysgerminomas: germ cell tumors exhibit high expression of PD-L1 and associated with high TILs and good prognosis.Sci Rep. 2024 Oct 15;14(1):24191. doi: 10.1038/s41598-024-74192-z. Sci Rep. 2024. PMID: 39406772 Free PMC article.
-
Hematopoietic and leukemic stem cells homeostasis: the role of bone marrow niche.Explor Target Antitumor Ther. 2024;5(5):1027-1055. doi: 10.37349/etat.2024.00262. Epub 2024 Aug 15. Explor Target Antitumor Ther. 2024. PMID: 39351440 Free PMC article. Review.
-
Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study.Adv Ther. 2024 Nov;41(11):4153-4171. doi: 10.1007/s12325-024-02981-z. Epub 2024 Sep 14. Adv Ther. 2024. PMID: 39276185 Clinical Trial.
-
Identifying ADGRG1 as a specific marker for tumor-reactive T cells in acute myeloid leukemia.Exp Hematol Oncol. 2024 Sep 6;13(1):92. doi: 10.1186/s40164-024-00560-0. Exp Hematol Oncol. 2024. PMID: 39243082 Free PMC article.
-
Evolution of natural killer cell-targeted therapy for acute myeloid leukemia.Int J Hematol. 2024 Jul;120(1):34-43. doi: 10.1007/s12185-024-03778-0. Epub 2024 May 1. Int J Hematol. 2024. PMID: 38693419 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials